COPD study investigates role of fibrocytes in lung scarring
NCT ID NCT01692444
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at fibrocytes—cells involved in scarring—in the lungs and blood of 50 people with COPD compared to healthy controls. Researchers want to understand how these cells contribute to airway remodelling, the abnormal tissue repair that makes COPD worse. The goal is to find new clues for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this study clarifies how fibrocytes contribute to COPD airway damage, it could point toward new drug targets for slowing disease progression.
- What could go wrong
- This is a small, observational study (50 participants) that only measures cells, not treatments. It may not lead to any therapy, and findings may not apply to all COPD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University hospital of Bordeaux, Hôpital du Haut Lévêque
Pessac, 33604, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD